Eli Lilly Says Its New Weight-Loss Pill Is Highly Effective
The drug, called orforglipron, differs from Lilly's injectable drug, tirzepatide (which is approved as Mounjaro to treat diabetes and as Zepbound to treat obesity and some forms of obstructive sleep apnea). While tirzepatide targets two hormones, GLP-1 and GIP, orforglipron just targets GLP-1. Lilly and other companies that make similar medicines have been racing to create oral weight-loss drugs, since weekly injections are not always appealing to patients.
The trial included more than 3,100 overweight or obese adults who had an obesity-related medical problem but not diabetes. Those taking the pill daily for almost a year and a half lost 12% of their body weight on average, or 27 pounds. People taking a placebo lost just over two pounds. The findings have not yet been published in a peer-reviewed journal but will be presented in September at the annual meeting of the European Association for the Study of Diabetes.
Based on the results, Lilly says it plans to file for approval of orforglipron from the U.S. Food and Drug Administration to treat obesity by the end of the year. If approved, Lilly says, it will be able to provide the pills by next year. The company is waiting for final results from a similar study of weight loss in people with diabetes; early results released in April indicate that the drug helped people with diabetes lower their blood sugar.
'The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, Lilly's chief scientific officer. 'The safety, tolerability, and efficacy were all in line with what we achieved with the injectable drug, yet now delivered in an easy-to-use, once-a-day pill.'
Read More: The Health Risks and Benefits of Weight-Loss Drugs
Among people in the study who took the drug, risk factors for heart disease such as LDL cholesterol, triglycerides, blood pressure, and a marker of inflammation also dropped, Skovronsky notes. That supports earlier data finding that GLP-1 drugs can lower the risk of heart disease as well.
As with the injectable form, people taking the pills had to gradually increase their dose before reaching the maximum dose, mainly to minimize the side effects of gastrointestinal distress. In the study, people started out at 6 mg, then increased to 12 mg four weeks later, then to the maintenance dose of 36 mg four weeks after that.
Orforglipron's side effect profile was similar to that of the injectable drugs, which is reassuring, says Skovronsky. 'There were two things I worried about,' he says. 'One, when you take something orally, you are exposing the stomach and intestines to a higher concentration of the drug. If that's where the side effects are caused, then [the oral] form could make them worse. But it wasn't the case at all.'
It also wasn't clear what would happen if people in the study missed doses, since it's sometimes challenging to take a pill every day. Because the dose is carefully titrated up, Skovronsky said it wasn't known if people who missed pills for a few days would lose the tolerance they had built up to the side effects and have to restart their dosing schedule. 'What we found was that the side effects were similar to the injections, even though people missed the dose every once in a while,' he says.
Read More: Is Ozempic the New Anti-Inflammatory Wonder Drug?
Novo Nordisk, a competitor that makes Ozempic for treating diabetes and Wegovy for weight management, also has an oral form of its active ingredient, semaglutide, that is already approved to treat diabetes. The company has applied for approval to treat obesity in people without diabetes and expects a decision by the end of the year.
If orforglipron is approved, it could increase access to GLP-1 medications in the U.S. and around the world. The oral drug is cheaper than the injectable, since it does not require a sterile injectable pen. Some people are also reluctant to inject themselves weekly, so taking the medication by mouth would be a welcome option.
As more doctors and patients figure out the best way to use GLP-1 drugs to manage weight, a pill could either kickstart weight loss or become part of a long-term maintenance program for people who have hit their weight-loss goal. 'This can enable us to go earlier in the disease course, because people sometimes hold off on the injections until the disease—in this case, obesity—is more severe,' says Skovronsky. 'We want to treat obesity at its earliest stages, and this provides a good opportunity to do that.' Skovronsky says Lilly is also studying weight-maintenance approaches with orforglipron.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
23 minutes ago
- New York Post
Ozempic users aged backwards by more than 3 years in new trial
An astonishing new trial suggests that Ozempic may help users not only drop pounds but also turn back time. In the first trial to directly measure the impact of semaglutide on aging, half of the participants were given a weekly injection of Ozempic while the other half received a placebo for 32 weeks. 'Those on semaglutide drug became, on average, 3.1 years biologically younger by the end of the study,' diagnostic researcher Varun Dwaraka reported. The placebo group showed no significant change in biological age over the same period. Researchers believe these powerful anti-aging qualities are related to Ozempic's effect on fat distribution and metabolic health. millaf – While everyone knows their chronological age, medical experts often speak in terms of biological or 'phenotypic' age, which measures factors like metabolism, inflammation, and organ function. Researchers note that the anti-aging effects of GLP-1 varied across the body's systems. The most dramatic improvements were to the brain and inflammatory system, where the drug, originally developed to treat diabetes, appeared to delay biological aging by nearly 5 years. The teams also noted significant improvement in the heart and kidneys. 'The drug may not only slow the rate of aging, but in some individuals partially reverse it,' Dwaraka said. Researchers believe these powerful anti-aging qualities are related to Ozempic's effect on fat distribution and metabolic health. In essence, excess fat around the body's organs promotes the release of pro-aging molecules. Obesity causes low-grade chronic inflammation, which is when the body's natural chemical response to an irritant or injury remains active long after the threat has passed. GLP-1 drugs indirectly reduce inflammation through weight loss. The meds can also activate specific T cells — white blood cells key to the immune system — which can have anti-inflammatory effects. 'The drug may not only slow the rate of aging, but in some individuals partially reverse it,' a researcher on the study said. Ilzer/ – By reducing excess fat and inflammation, two hallmarks of epigenetic aging, the drug effectively slows the cruel march of deterioration. The use of GLP-1 medications has proliferated in recent years. A recent KFF health poll revealed that 12% of US adults have taken an Ozempic-like drug at some point. Despite the promising results, Dwaraka said caution and patience are called for. 'Prescribing it more broadly as an anti-ageing therapy is premature,' he said. However, he and his team are hopeful their research will inspire further studies and support the repurposing of existing drugs to treat age-related problems, as these established medications are more likely to be fast-tracked for approval and come without the risk of unforeseen side effects. 'Semaglutide may well emerge as one of the most promising candidates in this space,' Dwaraka concluded. GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk and decreased cancer risk to addiction treatment.
CNBC
a day ago
- CNBC
From Starbucks to Smoothie King, restaurants seek to cash in on consumers' protein frenzy
Restaurant chains are joining in on the protein frenzy, hoping to encourage diners to pay more for extra macronutrients during a time when many consumers aren't spending as much. From "gym bros" to users of GLP-1 drugs like Ozempic, many Americans are trying to add more protein to their diets, with the goal of building or maintaining their muscle mass and feeling more satiated after meals. Moreover, diet trends that don't emphasize protein intake, such as the ketogenic diet, have fallen out of favor. "A lot of younger consumers are more proactive about their health habits, so they're looking for ways to support health now but also to support their health in the future," said Julia Mills, a food and drink analyst for market research firm Mintel. "Generation Alpha, Gen Z, millennials — these consumers are very active on social media, so they're constantly being fed this message that you need more protein, and protein helps you gain muscle and makes you stronger." Roughly a third of consumers said they loved high protein in the second quarter of 2025, up from 24% three years ago, according to Datassential, which tracks restaurant menus and consumer preferences. The trend has fueled a protein takeover in grocery store aisles, from protein-packed Eggo waffles to Khloe Kardashian's Khloud protein popcorn. But it's also hitting the menus of restaurants that are seeking ways to encourage diners to pay for premium food and drinks. Take Starbucks, for example. The coffee giant said in late July that it will roll out a cold foam packed with 15 grams of protein later this year; the regular cold foam add-on typically costs customers an extra $1.25 per drink. The new foam comes as the chain's U.S. sales have been shrinking for the past year as coffee drinkers brew their java at home or seek out trendier options. Rival Dutch Bros launched a protein coffee in early 2024 and charges customers an extra $1 for the customization. The menu addition fueled strong same-store sales growth and profits for the upstart chain. Eateries are seeking to attract diners like Jared Hutkowski, a 42-year-old director of brokerage in Harrisburg, Pennsylvania. He works out six days a week and tries to hit his daily protein goal to improve his physique and overall health. When he dines out, he tries to maximize his protein, although he sometimes goes for pizza anyway. "The biggest factor is what I am in the mood for that day, and then I normally try and select a meal that has a least a serving of some type of protein in it," Hutkowski said. This year, 28.4% of U.S. restaurant menus call out "protein," up from 5.9% a decade ago, according to Datassential. And the trend looks like it has staying power. Datassential predicts that by 2029, more than 40% of eateries will highlight protein on their menus. "Protein is one of those things that's never been vilified, because no one's ever said that eating too much protein can be bad for you," Mintel's Mills said. In the short term, consuming more protein than your body needs likely won't cause health issues, but in the long term, it could cause kidney problems, according to Diane Han, a registered dietitian based in San Francisco and the founder of Woking Balance Wellness. The recommended daily amount of protein intake varies by body weight but is roughly 46 grams for women and 56 grams for men, according to the Centers for Disease Control and Prevention. For restaurants, protein's step change happened several years ago. In 2021, protein only had a menu penetration of 11.5%; by 2022, more than a quarter of restaurant menus used the term, based on Datassential data. That year, Dine Brands' IHOP, for example, introduced pancakes with 18 grams of protein per flapjack. Fast-casual eateries are the restaurant segment most likely to call out protein on their menus, thanks to the common practice of asking customers to pick their protein or offering to double their portion, according to Datassential. Fast-casual salad chain Sweetgreen introduced a line of "protein plates" in late 2023 as part of an effort to introduce more hearty options for dinner customers. The menu addition has helped the company grow its dinner business from 35% of sales to about 40%, executives said in March. Many restaurants are also leaning into U.S. consumers' desire for convenience. Accessibility may be why Datassential found that consumers tend to prefer protein-packed beverages. For Smoothie King, protein has been a menu staple since its founding more than 50 years ago. But in October, the chain took one step further, launching a menu aimed at consumers who take GLP-1 drugs for weight loss or diabetes. The rapid weight loss that can occur from the medications can cause muscle mass to drop, so doctors often advise patients to increase their protein intake to maintain their muscle. "It's a convenient, on-the-go way to get in your protein that you're looking for in your diet," said Lori Primavera, Smoothie King's vice president of research and development and product marketing. Many restaurants are also choosing to highlight existing protein-packed options, rather than adding new menu items that would slow down kitchens or add to much complexity to their operations. For example, Panda Express introduced its own protein plates earlier this year. The line, created in partnership with a registered dietitian, includes pre-existing menu items but packages them as a balanced meal, highlighting protein and fiber content. Chipotle Mexican Grill employed a similar strategy back in 2019 when it introduced "lifestyle bowls," marketed to fit different dietary goals, like the paleo diet or offering double protein. Likewise, in July, Chick-fil-A put the spotlight on its own high-protein options in a company blog, highlighting its grilled nuggets and the Cool Wrap, which features a grilled chicken breast, cheese and lettuce in a tortilla. But for the eateries that want to add new menu items, nachos with a choice of protein, restaurant-made protein bars and egg dishes that highlight high protein content are all increasingly popular options, according to Datassential trendologist Claire Conaghan. Eggs are one reason why breakfast, brunch and lunch eatery First Watch has always been "protein forward," CEO Chris Tomasso told CNBC. The chain hasn't adjusted its menu specifically to address consumers' demand for more protein, but TikTok influencers have highlighted how to order a high-protein meal when visiting its restaurants. "We hope that continues to be a trend because we're right down the middle of the fairway on that," Tomasso said. Of course, protein isn't the only way to win over health-conscious consumers. Hutkowski said his primary issue with eating at restaurants is that most of the food is cooked in oils, butter and heavy greases that rapidly add to his intake of fats for the day. "A restaurant finding cleaner ways to cook would be much more attractive to me than overly loaded protein dishes," he said.
Yahoo
a day ago
- Yahoo
Eli Lilly's Miracle Weight Loss Pill May Not Be Miraculous Enough
Eli Lilly shares looked like they'd been through an intensive Zepbound weight-loss treatment Thursday, losing 14% of their value on the New York Stock Exchange. Shareholders prefer their stocks to bulk up. The culprit was data for Lilly's weight loss pill, meant to expand the reach of its existing GLP-1 treatment for obesity. What it underscored is just how fierce, down to mere percentage points, the next several years of competition in the medical weight loss market will be. READ ALSO: Intel's CEO Lands in a Political Hot Seat Over Connections With China and Spacecraft-Maker Firefly Shoots for the Moon in Nasdaq Debut The Percentage Gap Lilly's second-quarter results reported Thursday were more than fine: $15.5 billion in revenue beat Wall Street estimates. And the company continued a streak of winning market share from its chief rival in the business of GLP-1s, which have been hailed as miracle drugs for their usefulness in treating diabetes and obesity. On Wednesday, Denmark's Novo Nordisk said GLP-1 diabetes drugs' sales growth slowed to just 8% in the second quarter, far behind the 21% posted last year. Sales of obesity drugs, including Wegovy, rose 56%, the same pace as last year. A day later, Lilly revealed that it continued to encroach on its rivals' market share in the second quarter, with Mounjaru revenue up 68% year-over-year to $5.2 billion and Zepbound revenue up 172% to $3.4 billion. The company raised its full-year guidance by $1.5 billion to between $60 billion and $62 billion. But then came the data everyone was anticipating. GLP-1s have become so popular that one in eight US adults, or 12%, told a poll by KFF Health last year that they had taken a GLP-1 drug before, while 6% said they were then using one. But the treatments are currently administered through a weekly injection, which companies say drives away patients averse to needles. To remedy that, Eli Lilly and Novo Nordisk have been developing GPL-1 pills, which could unlock billions in new sales. Morgan Stanley analysts previously said the bull case for Lilly's GLP-1 pill treatment for obesity and diabetes is $40 billion in annual sales by 2033. Thursday revealed a slight hitch: The pills have a problem: Lilly's orforglipron helped non-diabetic overweight or obese patients lose 12.4% of their weight in a late-stage study. Sounds great, except it's less than the 15% weight loss achieved by Novo Nordisk's oral version of Wegovy, for which that company is already seeking FDA approval. The performance gap was substantial enough to convince many investors that Novo's pill will have the upper hand when the two go to market. After the data was released, one analyst — David Risinger of Leerink Partners — cut his forecast for orforglipron's 2030 sales by 38% to $13.5 billion. And the Winner Is: Novo, at least for a day. Losing market share to Lilly and copycat drugmakers has weighed heavily on the company, with its shares falling over 43% this year. The news of the muted performance of its chief rival's GLP-1 pill sent Novo's shares up 7.5% on Thursday. Both treatments are still expected to be big earners, but Novo — which has also had to tangle with tariff threats this year, unlike US-based Lilly — can claim another small victory in the race to produce the biggest (weight) loser. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
